Abstract
The optimization of a series of 5-phenylacetyl 1,4,5,6-tetrahydropyrrolo[3, 4-c]pyrazole derivatives toward the inhibition of Aurora kinases led to the identification of compound 9d. This is a potent inhibitor of Aurora kinases that also shows low nanomolar potency against additional anticancer kinase targets. Based on its high antiproliferative activity on different cancer cell lines, favorable chemico-physical and pharmacokinetic properties, and high efficacy in in vivo tumor models, compound 9d was ultimately selected for further development.
| Original language | English |
|---|---|
| Pages (from-to) | 7247-7251 |
| Number of pages | 5 |
| Journal | Journal of Medicinal Chemistry |
| Volume | 49 |
| Issue number | 24 |
| Early online date | 1 Nov 2006 |
| DOIs | |
| Publication status | Published - 30 Nov 2006 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Cancer
- Inhibition
- Inhibitors
- Peptides and proteins
- Tumors
ASJC Scopus subject areas
- Molecular Medicine
- Drug Discovery
Fingerprint
Dive into the research topics of '1,4,5,6-Tetrahydropyrrolo[3,4-c]pyrazoles: Identification of a potent aurora kinase inhibitor with a favorable antitumor kinase inhibition profile'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver